SAN DIEGO--(BUSINESS WIRE)--Sep. 28, 2009-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today it will make multiple presentations at the Vaccine 3rd Global Congress being held in Singapore October 4th – 6th.
Inovio representatives will be making the following presentations regarding electroporation-delivered DNA vaccines:
Delivering on the Promise of DNA Vaccines for HIV and Cancer:
From Bench to Clinical Data
David Weiner
, Ph.D., Professor, University of Pennsylvania; Chairman, Scientific Advisory Board, Inovio Biomedical
Plenary Session 5, Novel Vaccines and Delivery Systems
Grand Ballroom
Monday, October 5
13:40
Development of Universal SynCon™ DNA Vaccines for Pandemic and Seasonal Flu
Niranjan Y. Sardesai
, Ph.D., Senior VP, R & D, Inovio Biomedical
Breakout Session 1, JSV Sponsored Session and Influenza
Grand Ballroom
Monday, October 5
17:20
The presentations will include progress on programs in Inovio’s pipeline. The congress program consists of invited lectures and presentations selected from submitted abstracts broadly covering vaccine development. The key objectives of the Vaccine 3rd Global Congress are to:
- provide a progressive state-of-the-art report for scientists, governmental authorities and healthcare workers
- accelerate progress in the development of vaccines
- encourage a prophylactic approach to healthcare.
More information on the Vaccine 3rd Global Congress and the overall program can be found at: http://www.vaccinecongress.com/.
About Inovio Biomedical Corporation
Inovio Biomedical is engaged in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. The company’s SynCon™ technology enables the design of DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens such as influenza. Inovio’s proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio’s clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Inovio is developing its universal and avian influenza vaccines in collaboration with scientists from the University of Pennsylvania and the National Microbiology Laboratory of the Public Health Agency of Canada. Other partners and collaborators include Merck, Tripep, University of Southampton, National Cancer Institute and HIV Vaccines Trial Network. More information is available at www.inovio.com.
This press release contains certain forward-looking statements relating to our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s combined technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2008, our Form 10-Q for the six months ended June 30, 2009, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.